KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced the acceptance of six abstracts for ePoster presentation at the 20^th German Allergy Congress taking place in Düsseldorf, Germany from October 2–4, 2025.

Details are as follows:

Thursday, October 2 at 4:00–5:15 pm CEST:

• Time to End of Progression of Hereditary Angioedema Attacks Treated with Sebetralstat: Markus Magerl, Inmaculada Martinez-Saguer, William R. Lumry, John Anderson, Jonathan A. Bernstein, Mauro Cancian, Danny M. Cohn, Henriette Farkas, Henry Li, James Hao, Michael Smith, Paolo Bajcic, Paul Audhya, Petra Staubach, Emel Aygören-Pürsün.
• Sebetralstat for On-demand Treatment of Hereditary Angioedema Attacks in European Participants: Interim Analysis from KONFIDENT-S: Inmaculada Martinez-Saguer, Petra Staubach, Teresa Caballero, Mar Guilarte, Ramon Lleonart Bellfill, James Hao, Michael Smith, Paul Audhya, Markus Magerl, Emel Aygören-Pürsün.
• Effectiveness of Sebetralstat for the On-demand Treatment of Mucosal Hereditary Angioedema Attacks: Interim Analysis from KONFIDENT-S: Emel Aygören-Pürsün, Inmaculada Martinez-Saguer, Jonathan A. Bernstein, Danny M. Cohn, Vesna Grivcheva-Panovska, William R. Lumry, Marc A. Riedl, Andrea Zanichelli, Laurence Bouillet, Ya-Hsiu Chuang, Michael D. Smith, Christopher M. Yea, Paul K. Audhya, Henriette Farkas, Petra Staubach, Markus Magerl.
• Impact of Oral Sebetralstat on Anxiety Associated with Hereditary Angioedema Attacks in the Phase 3 KONFIDENT Trial: Emel Aygören-Pürsün, Jonathan A. Bernstein, Timothy J. Craig, Paula J. Busse, Teresa Caballero, Danny M. Cohn, Mar Guilarte, Henriette Farkas, Douglas H. Jones, Sorena Kiani-Alikhan, Michael E. Manning, Marcus Maurer, Marc A. Riedl, Sinisa Savic, H. James Wedner, Patrick F. K. Yong, Andrea Zanichelli, Erik Hansen, James Hao, Michael D. Smith, Christopher M. Yea, Paul K. Audhya, William R. Lumry.
• Sebetralstat For Treatment of HAE Attacks in Patients Receiving Berotralstat: Interim Analysis From the KONFIDENT-S Open-label Study: Markus Magerl, Inmaculada Martinez-Saguer, Michael E. Manning, Marc A. Riedl, Raffi Tachdijan, H. Henry Li, H. James Wedner, Daniel F. Soteres, James Hao, Michael D. Smith, Paul K. Audhya, Tamar Kinaciyan, Petra Staubach, Emel Aygören-Pürsün.

Saturday, October 4 at 10:15–11:15 am CEST:

• Barriers to Timely Treatment of Hereditary Angioedema Attacks in German Patients: Thomas Buttgereit, Markus Magerl, Sherry Danese, Julie Ulloa, Paolo Bajcic, Paul K. Audhya, Inmaculada Martinez-Saguer.

Links to all presentations can be found on the KalVista website under Publications.

About Hereditary Angioedema

Hereditary angioedema (HAE) is a rare genetic disease resulting in deficiency or dysfunction in the C1 esterase inhibitor (C1INH) protein and subsequent uncontrolled activation of the kallikrein-kinin system. People living with HAE experience painful and debilitating attacks of tissue swelling in various locations of the body that can be life-threatening depending on the area affected. Treatment guidelines recommend treating attacks as early as possible to prevent progression of swelling and shorten the time to attack resolution, and to consider treatment for all attacks, regardless of anatomic location or severity.

About EKTERLY^® (sebetralstat)

EKTERLY (sebetralstat) is a novel plasma kallikrein inhibitor approved in the United States, European Union, United Kingdom and Switzerland for the treatment of acute attacks of hereditary angioedema (HAE) in people 12 years of age and older. EKTERLY is the first and only oral on-demand treatment for HAE, offering efficacious and safe treatment of attacks without the burden of injections. With ongoing studies exploring its use in children aged two to 11 and multiple regulatory applications under review in key global markets, EKTERLY has the potential to become the foundational therapy for HAE management worldwide. For more information, including the full U.S. Prescribing Information, visit EKTERLY.com.

About KalVista Pharmaceuticals, Inc.

KalVista is a global pharmaceutical company dedicated to delivering life-changing oral therapies for individuals affected by rare diseases with significant unmet needs. The KalVista team discovered and developed EKTERLY^®—the first and only oral on-demand treatment for hereditary angioedema (HAE)—and continues to work closely with the global HAE community to improve treatment and care for this disease around the world. For more information about KalVista, please visit www.kalvista.com and follow us on LinkedIn, X, Facebook and Instagram.

Forward-Looking Statements

This press release contains "forward-looking" statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "goal," "seek," "believe," "project," "estimate," "expect," "position," "strategy," "future," "likely," "may," "should," "will" and similar references to future periods. These statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from what we expect. Examples of forward-looking statements include, among others, information relating to our business and business plans, the success of our efforts to commercialize EKTERLY^® (sebetralstat), our ability to successfully obtain foreign regulatory approvals for sebetralstat, our expectations about the safety and efficacy of sebetralstat, the timing of clinical trials and their results, our ability to commence clinical studies or complete ongoing clinical studies, including our KONFIDENT-S and KONFIDENT-KID trials, and the ability of EKTERLY to treat HAE. Further information on potential risk factors that could affect our business and financial results are detailed in our filings with the Securities and Exchange Commission, including in our annual report on Form 10-K for the year ended April 30, 2025, our quarterly reports on Form 10-Q, and our other reports that we may make from time to time with the Securities and Exchange Commission. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250926150381/en/